Identifying HIV patients with an unfavorable cardiovascular risk profile in the clinical practice: Results from the SIMONE study

Journal of Infection

Volumn 57, Issue 1, 2008, Pages 33-40

  De Socio, Giuseppe Vittorio L ^a   Parruti, Giustino ^b   Quirino, Tiziana ^c   Ricci, Elena ^d   Schillaci, Giuseppe ^e   Adriani, Beatrice ^f   Marconi, Patrizia ^g   Franzetti, Marzia ^h   Martinelli, Canio ⁱ   Vichi, Francesca ^j   Penco, Giovanni ^k   Sfara, Claudio ^a   Madeddu, Giordano ^l   Bonfanti, Paolo ^d  

^a Santa Maria Hospital   (Italy)

^b Pescara Hospital   (Italy)

^c BUSTO ARSIZIO HOSPITAL   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e UNIVERSITY OF PERUGIA   (Italy)

^f Prato Hospital   (Italy)

^g NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^h UNIVERSITY HOSPITAL OF PADOVA   (Italy)

ⁱ CAREGGI UNIVERSITY HOSPITAL   (Italy)

^j SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

^k GALLIERA HOSPITAL   (Italy)

^l UNIVERSITY OF SASSARI   (Italy)

more..

Author keywords

Antiretroviral therapy; Arteriosclerosis; Cardiovascular disease; Framingham Risk Score; HIV; Lipodystrophy; Metabolic Syndrome

Indexed keywords

ANTIRETROVIRUS AGENT; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ACUTE DISEASE; ADULT; AGED; ALGORITHM; ARTICLE; CALCULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; CLINICAL FEATURE; CLINICAL PRACTICE; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISCHEMIC HEART DISEASE; ITALY; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PREVALENCE; PROBABILITY; SCORING SYSTEM; SMOKING;

ADULT; ALGORITHMS; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HIV-1; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; ITALY; MALE; MIDDLE AGED; RISK ASSESSMENT; RISK FACTORS; SMOKING;

EID: 46149110761     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2008.03.007     Document Type: Article

References (49)

1. Cammarosano C., and Lewis W. Cardiac lesions in acquired immune deficiency syndrome (AIDS). J Am Coll Cardiol 5 (1985) 703-706
2. Palella Jr. F.J., Delaney K.M., Moorman A.C., Loveless M.O., Fuhrer J., Satten G.A., et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338 (1998) 853-860
3. Grinspoon S., and Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 352 (2005) 48-62
4. Anderson K.M., Odell P.M., Wilson P.W., and Kannel W.B. Cardiovascular disease risk profiles. Am Heart J 121 (1991) 293-298
5. Wilson P.W., D'Agostino R.B., Levy D., Belanger A.M., Silbershatz H., and Kannel W.B. Prediction of coronary heart disease using risk factor categories. Circulation 97 (1998) 1837-1847
6. Grundy S.M., Cleeman J.I., Merz C.N., Brewer Jr. H.B., Clark L.T., Hunninghake D.B., et al. National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 (2004) 227-239
7. Stein J.H. Managing cardiovascular risk in patients with HIV infection. J Acquir Immune Defic Syndr 38 (2005) 115-123
8. Jericó C., Knobel H., Montero M., Ordoñez-Llanos J., Guelar A., Gimeno J.L., et al. Metabolic syndrome among HIV-infected patients: prevalence, characteristics, and related factors. Diabetes Care 28 (2005) 132-137
9. Bruno R., Gazzaruso C., Sacchi P., Zocchetti C., Giordanetti S., Garzaniti A., et al. High prevalence of metabolic syndrome among HIV-infected patients: link with the cardiovascular risk. J Acquir Immune Defic Syndr 31 (2002) 363-365
10. Bonfanti P., Giannattasio C., Ricci E., Facchetti R., Rosella E., Franzetti M., et al. HIV and metabolic syndrome: a comparison with the general population. J Acquir Immune Defic Syndr 45 (2007) 426-431
11. Eckel H.R., Grundy S.M., and Zimmet P.Z. The metabolic syndrome. Lancet 365 (2005) 1415-1428
12. Ford E.S. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 28 (2005) 1769-1778
13. Isomaa B., Almgren P., Tuomi T., Forsén B., Lahti K., Nissén M., et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24 (2001) 683-689
14. Executive Summary of the Third Report of the National Cholesterol Educational Programme (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
15. Friis-Moller N., Reiss P., Sabin C.A., Weber R., Monforte A., El-Sadr W., et al., DAD Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 356 (2007) 1723-1735
16. Mary-Krause M., Cotte L., Simon A., Partisani M., and Costagliola D. Clinical Epidemiology Group from the French Hospital Database. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 17 (2003) 2479-2486
17. De Socio G.V., Martinelli L., Morosi S., Fiorio M., Roscini A.R., Stagni G., et al. Is estimated cardiovascular risk higher in HIV-infected patients than in the general population?. Scand J Infect Dis 39 (2007) 805-812
18. Knobel H., Jericó C., Montero M., Sorli M.L., Velat M., Guelar A., et al. Global cardiovascular risk in patients with HIV infection: concordance and differences in estimates according to three risk equations (Framingham, SCORE, and PROCAM). AIDS Patient Care STDS 21 (2007) 452-457
19. Assmann G., Cullen P., and Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation 105 (2002) 310-315
20. [No authors listed]; Gruppo di Ricerca del Progetto CUORE. [The Italian Heart Project-longitudinal studies]. Ital Heart J 5 (2004) 94S-101S
21. Conroy R.M., Pyorala K., Fitzgerald A.P., Sans S., Menotti A., De Backer G., et al., SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 24 (2003) 987-1003
22. Bonfanti P., Ricci E., De Socio G., Zeme D., Carradori S., Penco G., et al. CISAI Study Group. Metabolic syndrome: a real threat for HIV-positive patients?: results from the SIMONE study. J Acquir Immune Defic Syndr 42 (2006) 128-131
23. Lichtenstein K.A., Ward D.J., Moorman A.C., Delaney K.M., Young B., Palella Jr. F.J., et al. HIV Outpatient Study Investigators. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS 15 (2001) 1389-1398
24. Galli M., Cozzi-Lepri A., Ridolfo A.L., Gervasoni C., Ravasio L., Corsico L., et al. LipoICoNa Study. Incidence of adipose tissue alterations in first-line antiretroviral therapy: the LipoICoNa Study. Arch Intern Med 162 (2002) 2621-2628
25. [No authors listed] The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 157 21 (1997) 2413-2446
26. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 26 (2003) 3160-3167
27. Ferrario M., Chiodini P., Chambless L.E., Cesana G., Vanuzzo D., Panico S., et al. CUORE Project Research Group. Prediction of coronary events in a low incidence population. Assessing accuracy of the CUORE Cohort Study prediction equation. Int J Epidemiol 34 (2005) 413-421
28. http://www.cuore.iss.it/eng/distribuzione/colesterolemia.asp.
29. Saves M., Chene G., Ducimetiere P., Leport C., Le Moal G., Amouyel P., et al. French WHO MONICA Project and the APROCO (ANRS EP11) Study Group. Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin Infect Dis 37 (2003) 292-298
30. Giavarina D., Barzon E., Cigolini M., Mezzena G., and Soffiati G. Comparison of methods to identify individuals at increased risk of cardiovascular disease in Italian cohorts. Nutr Metab Cardiovasc Dis 17 (2007) 311-318
31. Menotti A., Puddu P.E., and Lanti M. Comparison of the Framingham risk function-based coronary chart with risk function from an Italian population study. Eur Heart J 21 (2000) 365-370
32. Santos J., Palacios R., Gonzalez M., Ruiz J., and Marquez M. Atherogenic lipid profile and cardiovascular risk factors in HIV-infected patients (Netar Study). Int J STD AIDS 16 (2005) 677-680
33. Bergersen B.M., Sandvik L., Bruun J.N., and Tonstad S. Elevated Framingham risk score in HIV-positive patients on highly active antiretroviral therapy: results from a Norwegian study of 721 subjects. Eur J Clin Microbiol Infect Dis 23 8 (2004) 625-630
34. Kaplan R.C., Kingsley L.A., Sharrett A.R., Li X., Lazar J., Tien P.C., et al. Ten-year predicted coronary heart disease risk in HIV-infected men and women. Clin Infect Dis 45 (2007) 1074-1081
35. The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 349 (2003) 1993-2003
36. Law M.G., Friis-Moller N., El-Sadr W.M., Weber R., Reiss P., D'Arminio Monforte A., et al. DAD Study Group. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study. HIV Med 7 (2006) 218-230
37. [No authors listed] DECODE Study Group. Does diagnosis of the metabolic syndrome detect further men at high risk of cardiovascular death beyond those identified by a conventional cardiovascular risk score? The DECODE Study. Eur J Cardiovasc Prev Rehabil 14 (2007) 192-199
38. Wand H., Calmy A., Carey D.L., Samaras K., Carr A., Law M.G., et al. on behalf of the INITIO Trial International Coordinating Committee. Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. AIDS 21 (2007) 2445-2453
39. Mangili A., Jacobson D.L., Gerrior J., Polak J.F., Gorbach S.L., and Wanke C.A. Metabolic syndrome and subclinical atherosclerosis in patients infected with HIV. Clin Infect Dis 44 (2007) 1368-1374
40. Hadigan C., Meigs J.B., Corcoran C., Rietschel P., Piecuch S., Basgoz N., et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 32 (2001) 130-139
41. Freitas P, Carvalho D, Correia F, Marques R, Serrão R, Mota-Miranda A, et al. Patients with HIV associated lipodystrophy have an increased risk of cardiovascular disease [Abstract P121] Eighth International Congress on Drug Therapy in HIV Infection Glasgow UK 12-16 November 2006.
42. Samaras K., Wand H., Law M., Emery S., Cooper D., and Carr A. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia. Diabetes Care 30 (2007) 113-119
43. Chen M.P., Tsai J.C., Chung F.M., Yang S.S., Hsing L.L., Shin S.J., et al. Hypoadiponectinemia is associated with ischemic cerebrovascular disease. Arterioscler Thromb Vasc Biol 25 (2005) 821-826
44. Sweeney L.L., Brennan A.M., and Mantzoros C.S. The role of adipokines in relation to HIV lipodystrophy. AIDS 21 (2007) 895-904
45. Maggi P., Lillo A., Perilli F., Maserati R., and Chirianni A. on behalf of the PREVALEAT Group. Colour-Doppler ultrasonography of carotid vessels in patients treated with antiretroviral therapy: a comparative study. AIDS 18 (2004) 1023-1028
46. Floris-Moore M., Howard A.A., Lo Y., Arnsten J.H., Santoro N., and Schoenbaum E.E. Increased serum lipids are associated with higher CD4 lymphocyte count in HIV-infected women. HIV Med 7 (2006) 421-430
47. Dolan S.E., Hadigan C., Killilea K.M., Sullivan M.P., Hemphill L., Lees R.S., et al. Increased cardiovascular disease risk indices in HIV-infected women. J Acquir Immune Defic Syndr 39 (2005) 44-54
48. Schillaci G., Pirro M., Vaudo G., Gemelli F., Marchesi S., Porcellati C., et al. Prognostic value of the metabolic syndrome in essential hypertension. J Am Coll Cardiol 43 (2004) 1817-1822
49. Schillaci G., De Socio G.V., Pirro M., Savarese G., Mannarino M.R., Baldelli F., et al. Impact of treatment with protease inhibitors on aortic stiffness in adult patients with human immunodeficiency virus infection. Arterioscler Thromb Vasc Biol 25 (2005) 2381-2385